- Home
- KLRS vs QUMS Comparison
KLRS vs QUMS Comparison
Compare KLRS & QUMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | QUMS |
|---|---|---|
| Founded | 2019 | 2024 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 115.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KLRS | QUMS |
|---|---|---|
| Price | $6.34 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $20.67 | N/A |
| AVG Volume (30 Days) | ★ 58.0K | 14.4K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $9.94 |
| 52 Week High | $11.88 | $10.23 |
Technical Indicators
Market Signals| Indicator | KLRS | QUMS |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 70.30 |
| Support Level | $4.35 | N/A |
| Resistance Level | $7.20 | N/A |
| Average True Range (ATR) | 0.62 | 0.00 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 45.34 | 100.00 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About QUMS Quantumsphere Acquisition Corp. Ordinary Shares
Quantumsphere Acquisition Corp is a newly organized blank check company.